AIM ImmunoTech (AIM)

Executive Summary

AIM ImmunoTech Inc. is a clinical-stage immuno-pharma company focused on developing Ampligen® (rintatolimod), a broad-spectrum TLR3 agonist, for cancers, viral diseases, and immune disorders. The company's lead program targets pancreatic cancer, with additional studies in prostate cancer, chronic fatigue syndrome (CFS), and post-COVID conditions. Ampligen is already approved for severe CFS in Argentina, providing a commercial foothold. The company's strategy leverages Ampligen's versatile immunomodulatory properties to address multiple high-need indications. Financially, AIM operates on a tight budget with a market capitalization of approximately $4 million, reflecting its early stage and high risk. Key ongoing trials include a Phase 2 study of Ampligen combined with aspirin and interferon in prostate adenocarcinoma (NCT03899987), with expected completion in late 2026. The company also has a completed Phase 2 trial in long COVID and an active pre-clinical program in CFS. Despite limited pipeline breadth, AIM's focus on repurposing Ampligen across indications offers potential upside if clinical data prove positive.

Upcoming Catalysts (preview)

• Q1 2027Phase 2 Prostate Cancer Trial Data Readout30% success
• H2 2026Update on Pancreatic Cancer Program (New Trial Initiation or Data)20% success
• TBDRegulatory Progress for CFS (U.S. or EU Filing)15% success